AceConnex is a device intended for soft tissue surgical procedures, in which constructs are used for reconstruction, replacement, or augmentation of the labrum, and is offered in multiple pre-sutured lengths and diameters, with trimmable regions
AlloSource completes first implant of AceConnex device. (Credit: JAFAR AHMED on Unsplash)
US-based allografts provider AlloSource has announced the first implant of its AceConnex Pre-Sutured Fascia device for hip labral reconstruction and augmentation.
Dr Winston Gwathmey at the University of Virginia Health conducted the first labral reconstruction procedure using the AceConnex device, which is under limited market release.
The AceConnex device is intended for soft tissue surgical procedures, in which constructs are used for reconstruction, replacement, or augmentation of the labrum.
It is a ready-to-use, sterile device offered in multiple pre-sutured lengths and diameters, with trimmable regions that facilitate allograft adjustments to conform with patients’ anatomy.
The company said that the manufacturing of the AceConnex device ensures consistency and minimises variability compared to other allografts that are manually sutured pre-operatively.
Earlier this year, the AceConnex Pre-Sutured Fascia device was granted the US Food and Drug Administration (FDA) 510(K) approval for hip labral reconstruction and augmentation.
Gwathmey said: “I appreciated having AceConnex Pre-Sutured Fascia for this labral reconstruction procedure because it made my process in the operating room more efficient versus the extra time suturing myself.
“I am humbled to be the first surgeon in the United States to implant AceConnex. This device will be a true innovation for this procedure as it will allow the surgeon to eliminate the need to suture an allograft preoperatively.”
AlloSource chief commercial officer Kevin Whitten said: “The AceConnex Pre-Sutured Fascia allograft device represents a commitment to developing patient-specific solutions to treat hip labral injuries as part of our comprehensive sports medicine and hip arthroscopy portfolio.”
AlloSource is a Colorado-based non-profit organisation that provides human tissue allografts, along with advanced dermis, cartilage, tendon, fascia, bone, and amnion allografts for healing.
Recently, AlloSource has completed the first patient implantation of its ProChondrix CR Cryopreserved Osteochondral Allograft in an independent evaluation in the UK.
Nick Smith, a knee specialist orthopaedic surgeon at University Hospitals Coventry and Warwickshire, NHS Trust, has conducted the first procedure using ProChondrix CR.
The UK study is designed to evaluate the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care.